We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

A rough courtship

2 May 2014 By Neil Unmack

The U.S. drugmaker upped its proposal to $106 bln, and promised to keep some of the UK group’s workforce. It does not look high enough to bring Astra to the table. Worse, Pfizer’s aggressive public tactics may only antagonise shareholders.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)